切换至 "中华医学电子期刊资源库"
高级检索
中华结直肠疾病电子杂志

中华结直肠疾病电子杂志 ›› 2023, Vol. 12 ›› Issue (05) : 396 -403. doi: 10.3877/cma.j.issn.2095-3224.2023.05.006

论著

肝特异性转录因子FOXA2在人结直肠癌肝转移阶梯模型中的表达变化及其意义
黄怡诚, 陆晨, 孙司正, 喻春钊†()   
  1. 210011　南京医科大学第二附属医院普外科
    211112　南京医科大学附属逸夫医院普外科
    210011　南京医科大学第二附属医院普外科；211112　南京医科大学附属逸夫医院普外科
  • 收稿日期:2023-01-11 出版日期:2023-10-25
  • 通信作者: 喻春钊
  • 基金资助:
    江苏省第五期“333工程”科研项目(BRA2020091); 国家重点研发计划（政府间国际科技创新合作重点专项）(2018YFE0127300); 江苏省社会发展重点项目(BE2019759)

Expression of liver-specific transcription factors FOXA2 in human stepwise metastatic colorectal carcinoma model and its significance

Yicheng Huang, Chen Lu, Sizheng Sun, Chunzhao Yu†()   

  1. Department of General Surgery, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China
    Department of General Surgery, Sir Run Run Hospital of Nanjing Medical University, Nanjing 211112, China
    Department of General Surgery, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China; Department of General Surgery, Sir Run Run Hospital of Nanjing Medical University, Nanjing 211112, China
  • Received:2023-01-11 Published:2023-10-25
  • Corresponding author: Chunzhao Yu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

黄怡诚, 陆晨, 孙司正, 喻春钊. 肝特异性转录因子FOXA2在人结直肠癌肝转移阶梯模型中的表达变化及其意义[J/OL]. 中华结直肠疾病电子杂志, 2023, 12(05): 396-403.

Yicheng Huang, Chen Lu, Sizheng Sun, Chunzhao Yu. Expression of liver-specific transcription factors FOXA2 in human stepwise metastatic colorectal carcinoma model and its significance[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 396-403.

目的

探究人结直肠癌肝转移阶梯模型中FOXA2的表达变化及相关意义。

方法

采用Western blot技术和实时荧光定量PCR检测了常见结直肠癌细胞系中FOXA2的表达情况；在高表达细胞系SW-620细胞中转染FOXA2敲低质粒或阴性对照质粒，并用Western blot技术验证转染效果，以及检测上皮间质转化相关蛋白的表达变化。采用体内连续筛选法，通过在裸鼠体内进行SW-620结肠癌细胞株脾脏包膜下种植，经过连续三次肝转移筛选，构建结直肠癌肝转移阶梯模型。采用免疫组织化学染色法检测阶梯模型中肝转移瘤组织FOXA2的表达变化。采用Western blot技术检测模型中肝转移阶梯细胞的FOXA2、E-cadherin、N-cadherin、Vimentin、p-PI3K、p-Akt、PI3K、Akt相关蛋白的表达变化。采用划痕愈合实验方法分析模型中肝转移阶梯细胞迁移能力的变化。

结果

SW-620细胞中FOXA2的表达成功被下调后，E-cadherin表达上升，N-cadherin表达下降（P＜0.05）。在结直肠癌肝转移阶梯模型中，每一代肝转移瘤的成瘤率，转移灶数量，瘤体积逐渐升高（P＜0.05）；每一代肝转移瘤组织FOXA2免疫组化染色的阳性率逐渐升高（P＜0.05）；相对于初始SW-620细胞株，经过体内连续筛选的三代肝转移瘤细胞（CRLMC）中FOXA2表达呈现阶梯状上升趋势（P＜0.05），N-cadherin、Vimentin蛋白表达水平明显上升（P＜0.05）；E-cadherin蛋白表达水平明显下降（P＜0.05），p-PI3K/PI3K、p-AKT/AKT蛋白表达之比逐渐升高（P＜0.05）；划痕愈合实验显示每一代肝转移瘤细胞迁移能力逐渐增强（P＜0.05）。

结论

肝特异性转录因子FOXA2在人结直肠癌肝转移阶梯模型中的表达逐渐上升，促进了肝转移瘤细胞的上皮间质转化。

关键词: 结直肠肿瘤, FOXA2, 阶梯转移模型, SW-620细胞株, 上皮间质转化
Objective

To explore the expression of liver-specific transcription factors FOXA2 in human stepwise metastatic colorectal carcinoma model and its significance.

Methods

The expression of FOXA2 in common colorectal cancer cell lines was detected by Western blot and real-time fluorescent quantitative PCR; Transfect FOXA2 knockdown plasmid or negative control plasmid into the highly expressed SW-620 cells, and verify the transfection effect with Western blot. The expression changes of epithelial mesenchymal transformation related proteins was detected by Western blot. SW-620 ceils were transplanted into the spleen capsule of nude mice,then the liver metastatic cells were picked out and transplanted into the spleen capsule of new nude mice for two times. After three times of liver metastasis, the stepwise metastatic colorectal carcinoma model was established by in vivo selection. The Expression of FOXA2 in stepwise colorectal liver metastatic tumors were detected by Immunohistochemical staining. The expression of FOXA2、E-cadherin、N-cadherin、Vimentin、p-PI3K、p-Akt、PI3K、Akt in stepwise colorectal liver metastatic cells were detected by Western blot. The migration of stepwise colorectal liver metastatic cells were analyzed by wound healing assays.

Results

After down-regulating the expression of FOXA2 in SW-620 cells, the expression of EMT-related protein E-cadherin increased, while N-cadherin decreased significantly (P＜0.05). The tumor formation rate,number of metastases,tumor weight and the positive rate of FOXA2 immunohistochemical staining of each generation of stepwise liver metastases gradually increased (P＜0.05) in the model. After three times of liver metastasis, the expression of FOXA2, N-cadherin,Vimentin and the rate of p-PI3K/PI3K, p-AKT/AKT in colorectal liver metastatic cells screened continuously in vivo selection showed a stepwise upward trend compared with the initial SW-620 cell line (P＜0.05),while the E-cadherin protein expression decreased significantly (P＜0.05). Wound healing assays showed that stepwise colorectal liver metastatic cells (CRLMC) had stronger migration ability (P＜0.05).

Conclusion

The expression of liver-specific transcription factors FOXA2 gradually increased in human stepwise metastatic colorectal carcinoma model, which promoted the epithelial mesenchymal transformation of liver metastatic cells.

Key words: Colorectal neoplasms, FOXA2, Stepwise metastasis model, SW-620 cell line, EMT
图1 FOXA2在SW-620中高表达。1A：通过Western blot检测正常人结肠上皮细胞系NCM-460和结直肠癌细胞系中FOXA2的蛋白质水平；1B：正常人结肠上皮细胞系NCM-460和结直肠癌细胞系中FOXA2蛋白表达水平的直方图；1C：RT-qPCR检测正常人结肠上皮细胞系NCM-460和结直肠癌细胞系中FOXA2的相对mRNA表达水平的直方图。*P＜0.05，**P＜0.01，***P＜0.001，****P＜0.0001
图2 肝转移阶梯模型小鼠肝脏转移灶肿瘤情况
表1 阶梯状肝转移模型小鼠成瘤情况和转移灶情况统计
组别 造模数量（只） 成瘤数量（只） 肝转移率（%） 转移灶数量（个/每只） 转移瘤体积（mm3/每只）
第一代 P1 10 6 60 2.83±1.17 16.67±8.42
第二代 P2 10 8 80 6.13±2.23 206.82±81.16
第三代 P3 10 9 90 7.56±3.05 774.44±151.37
检验值 7.019 105.9
P值 ＜0.05 ＜0.01
图3 肝转移阶梯细胞转移能力越来越强。3A：通过Western blot检测SW-620和肝转移阶梯细胞中EMT标记物（E-cadherin、N-cadherin和Vimentin）的蛋白质表达水平；3B：SW-620和肝转移阶梯细胞中EMT标记物（E-cadherin、N-cadherin和Vimentin）蛋白表达水平的直方图；3C：通过Western blot检测SW-620和肝转移阶梯细胞中p-PI3K、PI3K、p-AKT、AKT的蛋白质表达水平；3D：SW-620和肝转移阶梯细胞中磷酸化蛋白与总蛋白比率的直方图；3E：划痕实验检测SW-620和肝转移阶梯细胞的迁移能力；3F：划痕实验中SW-620和肝转移阶梯细胞的24小时划痕愈合率的直方图。*P＜0.05，**P＜0.01
图4 FOXA2在肝转移阶梯模型中表达逐渐升高。4A：免疫组化染色检测FOXA2在结直肠癌阶梯肝转移组织中表达的阳性率（10×/40×）；4B：结直肠癌阶梯肝转移组织中FOXA2免疫组化染色阳性率的直方图；4C：通过Western blot检测SW-620和肝转移阶梯细胞中FOXA2的蛋白质表达水平；4D：SW-620和肝转移阶梯细胞中FOXA2蛋白表达水平的直方图。*P＜0.05，**P＜0.01
图5 干扰FOXA2影响SW-620的上皮间充质转化。5A：通过Western blot检测sh-FOXA2组和sh-NC组之间FOXA2敲低效率和EMT标记物（E-cadherin、N-cadherin和Vimentin）的不同蛋白水平；5B：sh-FOXA2组和sh-NC组中FOXA2和EMT标记物（E-cadherin、N-cadherin和Vimentin）蛋白表达水平的直方图。*P＜0.05，**P＜0.01
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]
Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer[J]. Ann Surg, 2006, 244(2): 254-259.
[3]
Adam R, de Gramont A, Figueras J, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus[J]. Cancer Treat Rev, 2015, 41(9): 729-741.
[4]
Sellner F, Thalhammer S, Klimpfinger M. Isolated pancreatic metastases of renal cell carcinoma-clinical particularities and seed and soil hypothesis[J]. Cancers (Basel), 2023, 15(2): 339.
[5]
Nord AS, Blow MJ, Attanasio C, et al. Rapid and pervasive changes in genome-wide enhancer usage during mammalian development[J]. Cell, 2013, 155(7): 1521-1531.
[6]
Heinz S, Romanoski CE, Benner C, et al. The selection and function of cell type-specific enhancers[J]. Nat Rev Mol Cell Biol, 2015, 16(3): 144-154.
[7]
D'Artista L, Moschopoulou AA, Barozzi I, et al. MYC determines lineage commitment in kras driven primary liver cancer development [J]. J Hepatol, 2023, 79(1): 141-149.
[8]
Huang P, He Z, Ji S, et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors[J]. Nature, 2011, 475(7356): 386-389.
[9]
Gao H, Yan Z, Sun H, et al. FoXA2 promotes esophageal squamous cell carcinoma progression by ZEB2 activation[J]. World J Surg Oncol, 2021, 19(1): 286.
[10]
Sahoo SS, Ramanand SG, Gao Y, et al. FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity[J]. J Clin Invest, 2022, 132(12): e157574.
[11]
Tomoshige K, Stuart WD, Fink-Baldauf IM, et al. FOXA2 cooperates with mutant KRAS to drive invasive mucinous adenocarcinoma of the lung[J]. Cancer Res, 2023, 83(9): 1443-1458.
[12]
Jin K, Gao W, Lu Y, et al. Mechanisms regulating colorectal cancer cell metastasis into liver (Review) [J]. Oncol Lett, 2012, 3(1): 11-15.
[13]
Wang Z, Kim SY, Tu W, et al. Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment[J]. Cell Metab, 2023: S1550-4131(23)00140-7.
[14]
Enquist IB, Good Z, Jubb AM, et al. Lymph node-independent liver metastasis in a model of metastatic colorectal cancer[J]. Nat Commun, 2014, 5: 3530.
[15]
Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis[J]. Cell, 2017, 168(4): 670-691.
[16]
Reymond N, d'Água BB, Ridley AJ. Crossing the endothelial barrier during metastasis[J]. Nat Rev Cancer, 2013, 13(12): 858-870.
[17]
Tammela T, Sage J. Investigating tumor heterogeneity in mouse models[J]. Annu Rev Cancer Biol, 2020, 4(1): 99-119.
[18]
Zhao Y, Li J, Li D, et al. Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers[J]. Semin Cancer Biol, 2020, 60: 334-343.
[19]
Iwafuchi-Doi M, Zaret KS. Pioneer transcription factors in cell reprogramming[J]. Genes Dev, 2014, 28(24): 2679-2692.
[20]
Lehner F, Kulik U, Klempnauer J , et al. The hepatocyte nuclear factor 6 (HNF6) and FOXA2 are key regulators in colorectal liver metastases[J]. FASEB J, 2007, 21(7): 1445-1462.
[21]
Lehner F, Kulik U, Klempnauer J, et al. Inhibition of the liver enriched protein FOXA2 recovers HNF6 activity in human colon carcinoma and liver hepatoma cells[J]. PLoS One, 2010, 5(10): e13344.
[22]
Wang B, Liu G, Ding L, et al. FOXA2 promotes the proliferation, migration and invasion, and epithelial mesenchymal transition in colon cancer[J]. Exp Ther Med, 2018, 16(1): 133-140.
[23]
Teng S, Li YE, Yang M, et al. Tissue-specific transcription reprogramming promotes liver metastasis of colorectal cancer[J]. Cell Res, 2020, 30(1): 34-49.
[1] 罗青杉, 梅海涛, 郝家领, 蔡锦锋, 周润楷, 温玉刚. 连接蛋白43通过调控细胞周期抑制结直肠癌的增殖机制研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 344-349.
[2] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[3] 谢丽春, 欧庆芬, 张秋萍, 叶升. 简化和标准肝脏MRI方案在结直肠癌肝转移患者随访中的临床应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 434-437.
[4] 施烨鑫, 马翔, 鲁明, 夏青城, 王鹏超, 宋青雨, 赵庆洪. 腹腔镜下结直肠肿瘤定位研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 463-466.
[5] 任江波, 李丽, 王萍. 阻断PI3K/Akt信号通路促进低表达FoxA2肝脏前体细胞对分化诱导剂应答并朝肝细胞方向分化[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 336-343.
[6] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[7] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[8] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[9] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[10] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[11] 任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[12] 张迪, 王春霞, 张学东, 李发馨, 庞淅文, 陈一锋, 张维胜, 王涛. 梗阻性左半结直肠癌自膨式金属支架置入后行腹腔镜手术与开腹手术的短期临床疗效比较[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 375-380.
[13] 张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[14] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[15] 季鹏程, 鄂一民, 陆晨, 喻春钊. 循环外泌体相关生物标志物在结直肠癌诊断中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 265-273.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号